GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Generate Biomedicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.56+0.47 (+3.89%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
77.9%
100M of 128M shares
Institutional holders
86
42 new, 13 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
12 buys · 1 sales
Net bought $150.28M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nally Michael | 6,919,051 | 5.20% | 13G (passive) | Mar 31, 2026 |
| Afeyan Noubar | 62,701,915 | 48.90% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GENB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 62,673,117 | 48.83% | $1.06B | – | 68.66% |
| FMR LLC | 5,221,599 | 4.07% | $88.09M | +1,004,075 | 0.00% |
| Capital World Investors | 4,215,632 | 3.28% | $71.12M | +211,483 | 0.01% |
| Braidwell LP | 3,283,844 | 2.56% | $55.40M | −309,155 | 2.05% |
| Price T Rowe Associates Inc /Md/ | 2,156,627 | 1.68% | $36.38K | +46,994 | 0.00% |
| Norges Bank | 2,094,616 | 1.63% | $35.34M | New | 0.00% |
| ARCH Venture Management, LLC | 1,944,426 | 1.51% | $32.80M | – | 2.98% |
| HarbourVest Partners LLC | 1,722,210 | 1.34% | $29.05M | – | 17.09% |
| BlackRock, Inc. | 1,659,966 | 1.29% | $28.00M | New | 0.00% |
| Baker Bros. Advisors LP | 1,423,602 | 1.11% | $24.02M | – | 0.12% |
| JPMorgan Chase & Co | 1,409,649 | 1.10% | $23.84M | −1,537,610 | 0.00% |
| Deep Track Capital, LP | 1,333,815 | 1.04% | $22.50M | New | 0.33% |
| ARK Investment Management LLC | 1,284,617 | 1.00% | $21.67M | +786,209 | 0.14% |
| Vanguard Capital Management LLC | 1,132,750 | 0.88% | $19.11M | +1,001,431 | 0.00% |
| Harvard Management Co Inc | 1,111,100 | 0.87% | $18.74M | – | 0.44% |
| Nvidia Corp | 833,325 | 0.65% | $14.06M | – | 0.02% |
| Davern Capital Partners, LP | 824,679 | 0.64% | $13.91M | +232,879 | 2.37% |
| Siren, L.L.C. | 736,104 | 0.57% | $12.42M | – | 0.25% |
| Geode Capital Management, LLC | 735,003 | 0.57% | $12.40M | +616,760 | 0.00% |
| State Street Corp | 526,565 | 0.41% | $8.88M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 86 | 100M | 77.9% | 42 / 24 | 10 / 13 | 11M | 4M |
| Q1 2026 | 57 | 93M | 72.3% | 57 / 0 | 0 / 0 | 93M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GENB | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 3,752,630 | 2.92% | $63.31M | 0.07% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,237,891 | 0.96% | $17.33M | 1.11% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 816,876 | 0.64% | $13.78M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 634,700 | 0.49% | $8.33M | 0.01% | May 31, 2026 |
| iShares Russell 2000 ETF | 617,886 | 0.48% | $10.42M | 0.01% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 580,246 | 0.45% | $9.79M | 0.38% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 314,964 | 0.25% | $5.31M | 0.04% | Jun 30, 2026 |
| Eaton Vance Worldwide Health Sciences Fund | 312,500 | 0.24% | $4.10M | 0.54% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 296,479 | 0.23% | $5.00M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 267,202 | 0.21% | $3.74M | 0.01% | Jul 31, 2026 |
| JPMorgan Small Cap Blend Fund | 184,432 | 0.14% | $3.11M | 0.18% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 177,236 | 0.14% | $2.33M | 0.01% | May 31, 2026 |
| American Funds U.S. Small & Mid Cap Equity Fund | 174,326 | 0.14% | $2.29M | 0.33% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 169,300 | 0.13% | $2.22M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 157,860 | 0.12% | $2.66M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Nally | Chief Executive Officer, Director | 2,889,154 | 2.25% | Mar 6, 2026 |
| Gevorg Grigoryan | Chief Technology Officer | 659,973 | 0.51% | Mar 2, 2026 |
| Beth Grous | Chief People Officer | 300 | 0.00% | Mar 2, 2026 |
| Laurie Anne Lee | Chief Medical Officer | – | – | Mar 2, 2026 |
| Jason Silvers | President & CFO | 1,500 | 0.00% | Mar 2, 2026 |
| Sean Martin | Chief Legal Officer & GC | – | – | Mar 2, 2026 |
| Aarif Khakoo | Chief Scientific Officer | – | – | Feb 26, 2026 |
| Frances Arnold | Director | 463,944 | 0.36% | Sep 3, 2026 |
| Paul Gray Parker | Director | – | – | Mar 2, 2026 |
| Nancy A. Simonian | Director | – | – | Mar 2, 2026 |
| Jane L. Mendillo | Director | 1,500 | 0.00% | Mar 2, 2026 |
| Marsha Fanucci | Director | – | – | Mar 2, 2026 |
| Rupert Vessey | Director | – | – | Mar 2, 2026 |
| Noubar Afeyan | Director, 10% owner | – | – | Mar 2, 2026 |
| Stephane Bancel | Director | 1,184,989 | 0.92% | Mar 2, 2026 |
| Pioneering Medicines 02, LLC | 10% owner | 1,562,500 | 1.22% | Mar 12, 2026 |
| Pioneering Fund VII General Partner LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering Fund VII, L.P. | 10% owner | – | – | Mar 2, 2026 |
| Pioneering Special Opportunities Fund II General Partner LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | 10% owner | – | – | Mar 2, 2026 |
| Fpn Ii, L.P. | 10% owner | – | – | Mar 2, 2026 |
| VentureLabs VI LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering Fund VI, L.P. | 10% owner | 59,548,117 | 46.39% | Mar 2, 2026 |
| Pioneering Fund VI General Partner LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Nutritional Health LTP Fund, L.P. | 10% owner | 25,016,458 | 19.49% | Mar 2, 2026 |
| Health LTP Fund General Partner LLC Nutritional | 10% owner | 62,673,117 | 48.83% | Mar 2, 2026 |
| VentureLabs VI Manager LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| General Partner LLC FPN | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering, LLC | 10% owner | – | – | Mar 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Frances Arnold Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1,000 | $16.00 | $16.00K | 231,472 |
| Michael Nally Chief Executive Officer, Director | Mar 4, 2026 | Buy | +20,000 | $12.00 | $240.00K | 572,707 |
| Michael Nally Chief Executive Officer, Director | Mar 2, 2026 | Conversion | +658,327 | – | – | 1,316,654 |
| Stephane Bancel Director | Mar 2, 2026 | Conversion | +724,160 | – | – | 724,160 |
| Beth Grous Chief People Officer | Mar 2, 2026 | Buy | +300 | $16.00 | $4.80K | 300 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +13,702,224 | – | – | 13,702,224 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +987,491 | – | – | 987,491 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 15,264,724 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 4,340,252 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 1,562,500 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +12,723,940 | – | – | 12,723,940 |
| Jane L. Mendillo Director | Mar 2, 2026 | Buy | +1,500 | $16.00 | $24.00K | 1,500 |
| Jason Silvers President & CFO | Mar 2, 2026 | Buy | +500 | $16.00 | $8.00K | 500 |
| Jason Silvers President & CFO | Mar 2, 2026 | Buy | +500 | $16.00 | $8.00K | 500 |
| Jason Silvers President & CFO | Mar 2, 2026 | Buy | +1,000 | $16.00 | $16.00K | 1,000 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 4,340,252 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 15,264,724 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 1,562,500 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +13,702,224 | – | – | 13,702,224 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +12,723,940 | – | – | 12,723,940 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +987,491 | – | – | 987,491 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Frances Arnold Director | Sep 2, 2026 | 32,210 | $520.63K | Sep 2, 2026 | Restricted Stock Vesting |
| Frances Arnold Director | Sep 1, 2026 | 1,000 | $16.00K | Sep 1, 2026 | Restricted Stock Vesting |